Literature DB >> 6353525

Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

C S Bryan, K L Reynolds, E R Brenner.   

Abstract

Over the five-year period 1977-1981, we studied 1,186 episodes of bacteremia due to Enterobacteriaceae and Pseudomonadaceae in the four non-university hospitals of a single metropolitan area. Overall patient mortality was 36.3%, and mortality attributed specifically to infection was 19.0%. The importance of severity of underlying disease, site of infection, microorganism, and age--previously determined to be prognostic factors in studies conducted at tertiary-care centers--was confirmed. Appropriate initial antimicrobial therapy (defined as the administration of an effective agent in adequate dose and by a suitable route of administration on the first calendar day on which blood cultures were positive) did not improve survival compared with the use of an ineffective antimicrobial agent or no therapy at all. However, appropriate antimicrobial therapy subsequent to the first calendar day on which blood cultures were positive clearly affected survival. These findings confirm previous conclusions regarding the frequency and severity of gram-negative bacteremia and the overall impact of antimicrobial therapy on this condition. These studies also suggest the possibility that the definition of optimal initial therapy in some groups of patients should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353525     DOI: 10.1093/clinids/5.4.629

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  94 in total

1.  Virulence of silver-resistant mutant of Klebsiella pneumoniae in burn wound model.

Authors:  L K Gupta; R Jindal; H K Beri; S Chhibber
Journal:  Folia Microbiol (Praha)       Date:  1992       Impact factor: 2.099

2.  Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.

Authors:  Y Hirakata; M Kaku; K Tomono; K Tateda; N Furuya; T Matsumoto; R Araki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 3.  Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.

Authors:  J D Baumgartner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

Review 4.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

5.  Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide.

Authors:  R L Danner; K A Joiner; M Rubin; W H Patterson; N Johnson; K M Ayers; J E Parrillo
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Vaccination against Klebsiella aerogenes.

Authors:  E A Roe; R J Jones
Journal:  J Hyg (Lond)       Date:  1984-10

7.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

Review 8.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X.

Authors:  R L Danner; K A Joiner; J E Parrillo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

10.  Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Authors:  Kerri A Thom; Michelle D Shardell; Regina B Osih; Marin L Schweizer; Jon P Furuno; Eli N Perencevich; Jessina C McGregor; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.